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A BS TR AC T
BACKGROUND
Co-trimoxazole (fixed-dose trimethoprim–sulfamethoxazole) prophylaxis admin-
istered before antiretroviral therapy (ART) reduces morbidity in children infected 
with the human immunodeficiency virus (HIV). We investigated whether children 
and adolescents receiving long-term ART in sub-Saharan Africa could discontinue 
co-trimoxazole.
METHODS
We conducted a randomized, noninferiority trial of stopping versus continuing 
daily open-label co-trimoxazole in children and adolescents in Uganda and Zimba-
bwe. Eligible participants were older than 3 years of age, had been receiving ART 
for more than 96 weeks, were using insecticide-treated bed nets (in malaria-endemic 
areas), and had not had Pneumocystis jirovecii pneumonia. Coprimary end points were 
hospitalization or death and adverse events of grade 3 or 4.
RESULTS
A total of 758 participants were randomly assigned to stop or continue co-trimoxa-
zole (382 and 376 participants, respectively), after receiving ART for a median of 2.1 
years (interquartile range, 1.8 to 2.3). The median age was 7.9 years (interquartile range, 
4.6 to 11.1), and the median CD4 T-cell percentage was 33% (interquartile range, 26 
to 39). Participants who stopped co-trimoxazole had higher rates of hospitalization 
or death than those who continued (72 participants [19%] vs. 48 [13%]; hazard ratio, 
1.64; 95% confidence interval [CI], 1.14 to 2.37; P = 0.007; noninferiority not shown). 
There was no evidence of variation across ages (P  = 0.93 for interaction). A total of 
2 participants in the prophylaxis-stopped group (1%) died, as did 3 in the prophylaxis-
continued group (1%). Most hospitalizations in the prophylaxis-stopped group were 
for malaria (49 events, vs. 21 in the prophylaxis-continued group) or infections other 
than malaria (53 vs. 25), particularly pneumonia, sepsis, and meningitis. Rates of 
adverse events of grade 3 or 4 were similar in the two groups (hazard ratio, 1.20; 
95% CI, 0.83 to 1.72; P = 0.33), but more grade 4 adverse events occurred in the pro-
phylaxis-stopped group (hazard ratio, 2.04; 95% CI, 0.99 to 4.22; P = 0.05), with anemia 
accounting for the largest number of events (12, vs. 2 with continued prophylaxis).
CONCLUSIONS
Continuing co-trimoxazole prophylaxis after 96 weeks of ART was beneficial, as com-
pared with stopping prophylaxis, with fewer hospitalizations for both malaria and 
infection not related to malaria. (Funded by the United Kingdom Medical Research 
Council and others; ARROW Current Controlled Trials number, ISRCTN24791884.)
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Co-trimoxazole (fixed-dose trimetho-prim–sulfamethoxazole) is commonly used in sub-Saharan Africa because of its low 
cost, wide availability, and broad-spectrum anti-
microbial activity. Despite high levels of resis-
tance to co-trimoxazole, prophylaxis with this 
drug combination before antiretroviral therapy 
(ART) reduces mortality, morbidity, and rates of 
hospitalization among human immunodeficiency 
virus (HIV)–infected adults1-6 and children,7,8 pre-
dominantly by reducing rates of pneumonia, diar-
rhea, and malaria.1-8
The increasing availability of ART in sub-Saha-
ran Africa has considerably reduced morbidity and 
mortality among HIV-infected children.9 World 
Health Organization (WHO) guidelines10 recom-
mend daily co-trimoxazole prophylaxis for HIV-
infected children younger than 2 years of age 
and for those older than 2 years of age who have 
symptomatic disease or CD4 T-cell counts below 
age-related thresholds. However, the guidelines 
state that children older than 5 years of age who 
have good adherence to therapy during more 
than 6 months of ART, full clinical recovery, and 
a CD4 T-cell count of more than 350 per cubic 
millimeter may discontinue co-trimoxazole.11 
These guidelines are based on expert opinion and 
supported by observational data from Europe12 
and the United States13 showing that stopping 
co-trimoxazole with adequate CD4 T-cell recov-
ery does not increase the risk of Pneumocystis jir-
ovecii pneumonia or serious bacterial infection. 
However, to our knowledge, there have been no 
trials of the discontinuation of co-trimoxazole 
therapy in children and there are no data from 
sub-Saharan Africa, where bacterial infections 
are common and malaria is frequently endemic.
A systematic review14 of co-trimoxazole pro-
phylaxis along with the initiation of ART in HIV-
infected adolescents (>13 years of age) and 
adults in resource-limited settings showed a re-
duction in mortality of 58% (95% confidence 
interval [CI], 39 to 71). However, because most 
studies had short follow-up, the duration of ef-
fective treatment could not be determined; the 
longest study (median follow-up, 4.9 years) showed 
survival benefits of co-trimoxazole during 72 
weeks of ART but no effect thereafter.15 We re-
port the effect of stopping versus continuing 
co-trimoxazole prophylaxis in children and ado-
lescents who were receiving long-term ART in 
the Antiretroviral Research for Watoto (ARROW) 
trial16 in Uganda and Zimbabwe.
ME THODS
STUDY DESIGN
In this open-label, randomized, parallel-group 
trial, we enrolled HIV-infected children and ado-
lescents (≥3 years of age) who had been receiv-
ing ART within the ARROW trial for more than 
96 weeks at three centers in Uganda and one in 
Zimbabwe; the complete trial protocol is avail-
able with the full text of this article at NEJM.org. 
Participants were receiving daily co-trimoxazole 
prophylaxis (once-daily doses of 200 mg of sulfa-
methoxazole and 40 mg of trimethoprim, 400 mg 
of sulfamethoxazole and 80 mg of trimethoprim, 
or 800 mg of sulfamethoxazole and 160 mg of tri-
methoprim for a body weight of 5 to 15, 15 to 30, 
or >30 kg, respectively) and had an insecticide-
treated bed net if they were living in a malaria-
endemic area. Children and adolescents with 
previous P. jirovecii pneumonia were excluded.
Participants were randomly assigned in a 1:1 
ratio to continue to receive or to stop receiving 
prophylaxis. The hypothesis was that among 
patients who were receiving long-term ART, the 
outcomes in the group that stopped receiving 
prophylaxis would be similar to the outcomes in 
the group that continued to receive prophylaxis 
(i.e., cessation of prophylaxis would be noninfe-
rior to continued prophylaxis). Caregivers and 
participants who were 18 years of age or older by 
the time they were enrolled in the current study 
provided written informed consent; children and 
adolescents 7 to 17 years of age gave assent (de-
pending on their knowledge of HIV status).
The trial was approved by research ethics com-
mittees in Uganda, Zimbabwe, and the United 
Kingdom. ViiV Healthcare and GlaxoSmithKline 
donated antiretroviral agents. Co-trimoxazole 
was provided by national programs. The funders 
and medication donors had no role in any aspect 
of the study design, data accrual, data analysis, 
writing of the manuscript, or the decision to 
submit the manuscript for publication.
Randomization was stratified according to 
trial center and according to the randomization 
assignments in the overarching ARROW trial 
(see the Supplementary Appendix, available at 
NEJM.org). The computer-generated, sequential-
ly numbered randomization list (with variable 
block sizes) was prepared by the trial statistician 
and was incorporated within the secure database 
at each trial center. Randomization was performed 
by clinicians telephoning the local trial center. 
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Trial managers could access the next number on 
the list but not the whole list.
Participants visited a doctor and underwent a 
full blood count, CD4 T-cell count, and liver-func-
tion and renal-function tests (measurements of 
bilirubin, urea, creatinine, aspartate aminotrans-
ferase, and alanine aminotransferase levels) at 
randomization and every 12 weeks thereafter. 
The participants had follow-up visits every 6 weeks 
with a nurse who used a standard symptom 
checklist; ART and co-trimoxazole adherence 
were assessed by means of self-reported answers 
to questions about missed doses. Follow-up of 
the participants in the two study groups was 
continued until trial closure.
END POINTS
Coprimary end points were a first hospitaliza-
tion or death (efficacy) and adverse events of 
grade 3 or 4 that were not solely related to HIV 
infection (safety). Secondary end points included 
death, severe pneumonia, unexplained persistent 
diarrhea, clinical malaria, WHO stage 4 event or 
death, WHO stage 3 or 4 event or death, serious 
adverse events17 not solely related to HIV infec-
tion, growth (weight for age, height for age, and 
body-mass index for age), CD4 T-cell count, and 
adherence to ART (see the Supplementary Appen-
dix). Clinical events and severe adverse events 
were reviewed according to WHO criteria18 by an 
end-point review committee whose chair and 
members were independent of the study person-
nel and were unaware of the study assignments.
STATISTICAL ANALYSIS
We estimated that a target sample of 947 partici-
pants followed for 1.5 to 2.5 years, with a loss to 
follow-up of less than 10%, would provide 80% 
power to establish that cessation of co-trimoxa-
zole prophylaxis was noninferior to continued 
prophylaxis with respect to the primary efficacy 
end point (the rate of a first hospitalization or 
death). The noninferiority margin, chosen by a 
consensus of the investigators, was defined as 
the upper 95% confidence limit for a between-
group difference of no more than 3 events per 
100 participant-years, assuming a rate of 5 events 
per 100 participant-years among participants 
continuing to receive co-trimoxazole (see the 
Supplementary Appendix). Interim data were re-
viewed annually by an independent data-monitor-
ing committee (two meetings), with the use of 
the Haybittle–Peto criterion.19
All primary and secondary end points other 
than growth, CD4 T-cell count, and adherence 
to ART were compared between the randomized 
groups with the use of Kaplan–Meier plots, log-
rank tests, and proportional-hazards models 
(stratified according to the stratification factors 
at randomization), with time counted from ran-
domization to the first event, the last clinical 
assessment, or March 16, 2012 (trial closure), 
whichever was earliest. All comparisons were 
performed in the population of participants who 
underwent randomization (intention-to-treat 
analysis). The P values presented are from tests 
of the null hypothesis of no difference in effi-
cacy or safety between the randomized groups 
(i.e., tests of superiority); absolute differences in 
the event rates (with 95% confidence intervals) 
were estimated to explicitly address the original 
noninferiority hypothesis. Details of the statisti-
cal analyses are provided in the Supplementary 
Appendix.
R ESULT S
RANDOMIZATION AND FOLLOW-UP
A total of 1012 participants in the ARROW trial 
were approached for randomization in the current 
trial (Fig. 1), of whom 252 were not randomly 
assigned to a trial group, in most cases because 
their caregivers strongly believed that co-trimox-
azole was beneficial. From September 2009 
through February 2011, a total of 384 partici-
pants were randomly assigned to stop receiving 
co-trimoxazole, and 376 were randomly assigned 
to continue receiving co-trimoxazole. Of the par-
ticipants randomly assigned to stop receiving co-
trimoxazole, 2 were receiving dapsone prophy-
laxis and were excluded from the analysis; 758 
participants were included.
Baseline characteristics were generally balanced 
between the two groups (Table 1, and Table S1 
in the Supplementary Appendix). At randomiza-
tion, participants had a median age of 7.9 years 
(interquartile range, 4.6 to 11.1); 11% of the par-
ticipants were 13 years of age or older. In addi-
tion, participants had received ART for a median 
of 2.1 years (interquartile range, 1.8 to 2.3); 754 
participants (99%) were receiving first-line ART. 
A total of 38 participants (5%) had CD4 T-cell 
percentages of less than 15% at randomization, 
the median CD4 T-cell percentage was 33% (in-
terquartile range, 26 to 39), and the median CD4 
T-cell count in those older than 5 years of age was 
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720 per cubic millimeter (interquartile range, 489 
to 1055).
The median follow-up from randomization to 
the date of trial closure or the last date on which 
the participant was known to be alive was 2.1 
years (interquartile range, 1.8 to 2.2); the group 
in which prophylaxis was stopped had 763 par-
ticipant-years of follow-up, as compared with 759 
in the group that continued to receive prophy-
laxis. A total of nine participants withdrew from 
the study or were lost to follow-up (seven par-
ticipants in the prophylaxis-stopped group and 
two in the prophylaxis-continued group) (Fig. 1).
A total of 96.0% of the participant-time in 
this study was spent not receiving co-trimoxa-
zole in the prophylaxis-stopped group and 99.6% 
of the participant-time was spent receiving co-
trimoxazole in the prophylaxis-continued group. 
A total of 2 participants (1%) randomly assigned 
to stop co-trimoxazole never stopped, and 3 (1%) 
randomly assigned to continue prophylaxis sub-
sequently stopped; 22 participants (6%) randomly 
760 Underwent randomization
1206 HIV-infected children or adolescents
initiated ART and co-trimoxazole (if not
already receiving it) at enrollment
in main ARROW trial 
61 Died, were lost to follow-up, or withdrew
48 Died before 96 wk of ART or before
3 yr of age, whichever occurred later
13 Were lost to follow-up or withdrew
before 96 wk of ART or before 3 yr
of age, whichever occurred later
1145 Were included in follow-up at 96 wk of 
ART or 3 yr of age, whichever occurred later
133 Were not approached to undergo
randomization
1012 Were eligible and approached
to undergo randomization
252 Declined to participate
2 Underwent randomization
in error and were excluded
376 Were assigned to continue
co-trimoxazole prophylaxis
384 Were assigned to stop co-trimoxazole
prophylaxis
376 Continued co-trimoxazole
3 Stopped co-trimoxazole at any point after
randomization
2 Were not known to have died and were
last seen alive before end of study
380 Stopped co-trimoxazole
22 Started co-trimoxazole again at any
point after randomization
7 Were not known to have died and were
last seen alive before end of study
376 Were included in the analysis 382 Were included in the analysis
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assigned to stop prophylaxis subsequently re-
started it, mainly owing to concerns of the care-
giver or clinician (Fig. 1). A total of 21 partici-
pants (3%) began receiving second-line ART.
EFFICACY END POINTS
A total of 72 participants in the prophylaxis-
stopped group (19%) as compared with 48 in the 
prophylaxis-continued group (13%) reached the 
coprimary efficacy end point of hospitalization 
or death (hazard ratio, 1.64; 95% CI, 1.14 to 2.37; 
P = 0.007 by the log-rank test; 6.8 vs. 10.8 events 
per 100 participant-years; difference, 4.0 events 
per 100 participant-years [95% CI, 0.8 to 7.2], 
which was outside the noninferiority margin) 
(Fig. 2A and Table 2, and Table S2 in the Supple-
mentary Appendix). In prespecified subgroup 
analyses, there was no evidence (P>0.20 for inter-
action) that the efficacy of co-trimoxazole varied 
significantly according to age, sex, center, coun-
try, randomization year, baseline weight-for-age 
z score, CD4 T-cell count according to age, abso-
lute CD4 T-cell count, or routine or clinically 
driven laboratory monitoring or first-line ART 
strategy (Table 2, and Table S2 in the Supplemen-
tary Appendix).
Although there was some evidence of varia-
tion according to baseline CD4 T-cell percentage 
(P = 0.08 for interaction), the benefits of contin-
ued co-trimoxazole prophylaxis appeared to be 
greatest in participants with a CD4 T-cell per-
centage of 30% or more (hazard ratio for hospi-
talization or death in the prophylaxis-stopped 
group, 2.15; 95% CI, 1.30 to 3.54). The effects 
did not vary significantly over time (P = 0.14 by 
Schoenfeld’s test) (Fig. S1A in the Supplementa-
ry Appendix). A total of two participants in the 
prophylaxis-stopped group (1%) died (from in-
fection other than malaria in both), as did three 
in the prophylaxis-continued group (1%) (all from 
a noninfectious disorder).
Including the first and subsequent hospital-
izations, more hospitalizations and deaths oc-
curred during follow-up in the prophylaxis-
stopped group than in the prophylaxis-continued 
group (110 vs. 63 events), including hospitaliza-
tions for malaria (49 vs. 21) and for infection not 
related to malaria (53 vs. 25), particularly pneu-
monia, sepsis, and meningitis (Table S3 and Fig. 
S2 in the Supplementary Appendix). There was a 
trend toward more hospitalizations for severe 
malaria (grade 3 or 4 malaria, defined as pros-
tration, coma, shock, or respiratory distress) 
among participants in the prophylaxis-stopped 
group (24 of 49 hospitalizations for malaria 
[49%]), as compared with the prophylaxis-con-
tinued group (6 of 21 [29%]) (P = 0.11 by the 
chi-square test). In post hoc analyses, stopping 
co-trimoxazole was associated with an increased 
risk of hospitalization or death due to malaria 
Figure 1 (facing page). Study Enrollment, Randomization, 
and Follow-up.
Among 1145 participants in the Antiretroviral Re-
search for Watoto (ARROW) trial who had received 96 
weeks of antiretroviral therapy (ART) or were at least  
3 years of age, 133 were not approached to undergo 
randomization (e.g., because the participant attended 
the clinic without a caregiver who could be approached 
to provide informed consent). A total of 252 partici-
pants in the ARROW trial were eligible for randomiza-
tion but declined, predominantly because of strong 
caregiver beliefs in the benefits of co-trimoxazole.  
A total of 2 participants (both in the stop-treatment 
group) were receiving dapsone prophylaxis and had 
undergone randomization in error; they were not in-
cluded in the analysis. A total of 5 participants were 
ineligible for this study but were nevertheless included 
in the analysis: 2 participants (both in the prophylaxis-
continued group) had received less than 96 weeks of 
ART, and 3 (2 participants in the prophylaxis-stopped 
group and 1 in the prophylaxis-continued group) had 
received a diagnosis of Pneumocystis jirovecii pneumo-
nia; however, the diagnosis was not considered to be 
definitive, it occurred before enrollment, and it was 
not considered by the treating clinician to be plausible. 
In the prophylaxis-continued group, 1 participant tem-
porarily discontinued co-trimoxazole at randomization 
and restarted it 1 month later. In the prophylaxis-stopped 
group, 3 participants continued to receive co-trimoxa-
zole in error; 1 participant stopped prophylaxis 4 months 
after randomization, but the other 2 did not stop once 
the error was identified, owing to caregiver preference. 
In the prophylaxis-continued group, 3 participants 
stopped receiving co-trimoxazole (median duration  
of prophylaxis, 62 weeks [range, 42 to 78]); 2 partici-
pants stopped for approximately 6 weeks owing to 
clinic error, and 1 stopped intentionally when she be-
came pregnant. In the prophylaxis-stopped group, 22 
participants restarted co-trimoxazole (median duration 
until restarting, 30 weeks [range, 1 day to 95 weeks]). 
The reasons for restarting prophylaxis included care-
giver concern (in the case of 14 participants) and clini-
cian concern (in the case of 4: 1 with tuberculosis, 1 
with P. jirovecii pneumonia, and 2 with low CD4 T-cell 
counts); prophylaxis was temporarily restarted in 2 pa-
tients owing to clinic or caregiver error, and no reason 
was provided for 2. The study ended on March 16, 2012; 
the minimum follow-up was 48 weeks in the prophy-
laxis-continued group and 30 weeks in the prophylaxis-
stopped group.
The New England Journal of Medicine 
Downloaded from nejm.org on June 21, 2014. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 370;1 nejm.org january 2, 201446
(hazard ratio, 2.15; 95% CI, 1.22 to 3.78; P = 0.007 
by the log-rank test) and hospitalization or death 
due to infection other than malaria (hazard ratio, 
1.95; 95% CI, 1.15 to 3.32; P = 0.01 by the log-
rank test) (Table 2).
Malaria (diagnosed on the basis of character-
istic microscopical findings or a positive result 
of a rapid diagnostic test) was observed only in 
Uganda and was more frequent in the prophylaxis-
stopped group than in the prophylaxis-continued 
Table 1. Characteristics of the Participants at Randomization.*
Characteristic
Co-trimoxazole Prophylaxis 
Continued
(N = 376)
Co-trimoxazole Prophylaxis 
Stopped
(N = 382)
Female sex — no. (%) 195 (52) 203 (53)
Age — yr
Median 7.5 8.3
Interquartile range 4.6 to 11.1 4.5 to 11.0
Duration of ART — yr
Median 2.1 2.1
Interquartile range 1.8 to 2.3 1.8 to 2.3
Current ART regimen — no. (%)†
3TC–ABC–NVP 158 (42) 139 (36)
3TC–ABC–EFV 90 (24) 111 (29)
ZDV–3TC–ABC 125 (33) 126 (33)
Other first-line regimen 1 (<1) 4 (1)
LPV/r-containing second-line regimen 2 (1) 2 (1)
ART monitoring strategy — no. (%)‡
Laboratory and clinical monitoring 185 (49) 189 (49)
Clinically driven monitoring 191 (51) 193 (51)
CD4 T cells — %
Before ART§
Median 13 12
Interquartile range 8 to 18 8 to 18
Current
Median 33 32
Interquartile range 26 to 39 26 to 39
Current absolute CD4 T-cell count — cells/mm3
3–4 yr of age
Median 1493 1512
Interquartile range 1011 to 1904 1099 to 1931
5–7 yr of age
Median 1043 1091
Interquartile range 691 to 1432 709 to 1367
8–11 yr of age
Median 710 695
Interquartile range 516 to 957 482 to 985
≥12 yr of age
Median 567 562
Interquartile range 402 to 749 410 to 757
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group (119 episodes in 77 participants [20%] vs. 
50 episodes in 39 participants [10%]; hazard 
ratio, 2.21; 95% CI, 1.50 to 3.25; P<0.001 by the 
log-rank test) (Table 2 and Fig. 2B). The level of 
parasitemia was also higher in the prophylaxis-
stopped group than in the prophylaxis-contin-
ued group (median parasite density per 200 white 
cells, 221 [interquartile range, 61 to 1507] vs. 
153 [interquartile range, 23 to 710]; P = 0.04 by 
the rank-sum test). The increased risk after ces-
sation of co-trimoxazole prophylaxis persisted, 
with no evidence of significant variation over 
time (P = 0.70 by Schoenfeld’s test); however, ac-
cording to models explicitly estimating changes 
in risk over time,20 the excess risk appeared to 
be greatest early on (Fig. S1B in the Supplemen-
tary Appendix).
The frequency of other secondary end points 
was greater in the prophylaxis-stopped group than 
in the prophylaxis-continued group (Table S2 in 
the Supplementary Appendix); however, because of 
the low event rates, most differences were not sig-
nificant. Current or recent diarrhea was reported at 
follow-up visits in 57 participants in the prophy-
laxis-stopped group (15%), as compared with 38 
participants in the prophylaxis-continued group 
(10%) (P=0.05 by the chi-square test).
SAFETY END POINTS
For the coprimary safety end point, there were 
115 adverse events of grade 3 or 4 in 64 partici-
pants in the prophylaxis-stopped group (17%), as 
compared with 86 events in 55 participants in 
the prophylaxis-continued group (15%) (hazard 
ratio, 1.20; 95% CI, 0.83 to 1.72; P = 0.33 by the 
log-rank test) (Table 2, and Table S4 in the Sup-
plementary Appendix). Of these events, 37 in the 
prophylaxis-stopped group were grade 4, as com-
pared with 17 in the prophylaxis-continued group 
(hazard ratio, 2.04; 95% CI, 0.99 to 4.22; P = 0.05 
by the log-rank test). The greatest excess in grade 4 
adverse events was due to anemia (12 events in 
10 participants in the prophylaxis-stopped group 
[3%] vs. 2 events in 2 participants in the prophy-
laxis-continued group [1%]; P = 0.04 by Fisher’s 
exact test) (Table S5 in the Supplementary Appen-
dix). Only 1 participant (in the prophylaxis-stopped 
group) had adverse events of grade 3 or 4 (anemia, 
neutropenia, and presumed septicemia) that were 
adjudicated to be potentially related to co-tri-
moxazole; these events were also judged to be 
definitely related to zidovudine.
At 12 weeks after randomization, the hemo-
globin level had increased from baseline in the 
prophylaxis-continued group but not in the pro-
Table 1. (Continued.)
Characteristic
Co-trimoxazole Prophylaxis 
Continued
(N = 376)
Co-trimoxazole Prophylaxis 
Stopped
(N = 382)
Weight-for-age z score
Before ART§
Median −2.2 −2.2
Interquartile range −3.2 to −1.3 −3.3 to −1.3
Current
Median −1.3 −1.3
Interquartile range −1.9 to −0.6 −1.9 to −0.7
* 3TC denotes lamivudine, ABC abacavir, ART antiretroviral therapy, EFV efavirenz, LPV/r ritonavir-boosted lopinavir, 
NVP nevirapine, and ZDV zidovudine.
† During randomization for ART within the overarching Antiretroviral Research for Watoto (ARROW) trial, ART was initi-
ated with 3TC–ABC and a nonnucleoside reverse transcriptase inhibitor (NNRTI; either efavirenz or nevirapine) in one 
third of the participants and with ZDV–3TC–ABC and an NNRTI in two thirds. After 36 weeks, half the latter group dis-
continued ZDV and the other half discontinued the NNRTI (induction-maintenance strategy). NNRTIs were provided 
by local ministries of health. The regimen containing ritonavir-boosted lopinavir is a second-line therapy; other regi-
mens listed are first-line therapies.
‡ During randomization for the monitoring strategy within the overarching ARROW trial, participants were assigned to 
laboratory and clinical monitoring or to clinically driven monitoring alone. All the participants underwent CD4 T-cell, 
hematologic, and biochemical measurements every 12 weeks. All the results were returned for participants assigned to 
laboratory and clinical monitoring, but results were only returned for those assigned to clinically driven monitoring if 
they were requested for clinical reasons or if they indicated a grade 4 toxic event.
§  Measurements before the receipt of ART were conducted at the time of enrollment in the overarching ARROW trial.
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phylaxis-stopped group (mean [±SE] change, 
0.16±0.05 vs. −0.07±0.06 g per deciliter; adjusted 
P = 0.003); the between-group difference attenu-
ated after 12 weeks but remained significant 
overall (global P = 0.01 according to a general-
ized estimating equation that pools data across 
t-tests at each time point) (Fig. 3A). As compared 
with participants who continued to receive co-
trimoxazole, those who stopped receiving it had 
greater increases in the white-cell count and 
neutrophil count at 12 weeks (adjusted P = 0.009 
and 0.004, respectively) (Fig. S3A in the Supple-
mentary Appendix) and subsequently (global 
P<0.001 for both comparisons).
The increase in the CD4 T-cell percentage was 
slower in the prophylaxis-stopped group than in 
the prophylaxis-continued group, particularly ini-
tially (adjusted P = 0.01 at week 12; global P = 0.002) 
(Fig. 3B), but there were no significant differences 
between the groups in absolute CD4 T-cell counts 
(global P = 0.98) (Fig. S3B in the Supplementary 
Appendix). There was a trend toward small re-
ductions in the weight-for-age z score in partici-
pants who stopped receiving co-trimoxazole, as 
compared with those who continued to receive it 
(global P = 0.07) (Fig. 3C), but the height-for-age 
z score was similar in the two groups (global 
P = 0.19) (Fig. S3C in the Supplementary Appen-
dix), as was the body-mass-index according to 
age (global P = 0.34).
There was no significant difference between 
the prophylaxis-stopped group and the prophy-
laxis-continued group with respect to ART ad-
herence, as assessed on the basis of self-reported 
and caregiver-reported data at each follow-up 
visit for ART doses missed during the previous 
4 weeks (mean percentage of participants with 
missed doses after randomization, 7% and 8%, 
respectively; global P = 0.21). Before randomiza-
tion, similar proportions of participants in the 
prophylaxis-stopped group and the prophylaxis-
continued group reported missed co-trimoxa-
zole doses during the previous 4 weeks (mean, 
5% and 6%, respectively; global P = 0.26), and 
this rate remained similar in the prophylaxis-
continued group after randomization (mean, 6%). 
There were also no significant between-group 
differences in the number of missed doses over 
weekends or for 2 or more consecutive days 
(data not shown). During follow-up, the propor-
tion of caregivers and participants in Uganda 
who reported bed-net use every night in the 
previous week was higher in the prophylaxis-
stopped group than in the prophylaxis-contin-
ued group (mean, 99% vs. 98%; global P = 0.02).
DISCUSSION
In this randomized trial, we compared cessation 
of co-trimoxazole prophylaxis with continued 
prophylaxis in ART-treated children and adoles-
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Figure 2. First Hospitalization or Death and First Diagnostically Confirmed 
Episode of Malaria in Participants Who Continued or Stopped Co-trimoxazole 
Prophylaxis.
All hazard ratios were stratified according to randomization factors, with  
P values calculated from the stratified log-rank test. The number of pa-
tients who would need to be treated with co-trimoxazole for 1 year to pre-
vent a first hospitalization or death was 25 (Panel A); the number need to 
treat in order to prevent a first episode of malaria was 16 (Panel B).
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cents in sub-Saharan Africa, where the frequency 
of bacterial and protozoal infections is high. The 
study participants who stopped receiving co-tri-
moxazole after more than 2 years of ART had low 
mortality but had a sustained increase in the 
number of hospitalizations for malaria and for 
infection other than malaria during more than 
2 years of follow-up. There was no evidence of 
variation in the benefits of co-trimoxazole pro-
phylaxis across ages or CD4 T-cell values — a 
finding that is in agreement with the results ob-
served in adults in the Development of Antiretro-
viral Therapy in Africa trial.15
Existing recommendations11 regarding the 
discontinuation of co-trimoxazole in children in 
resource-limited settings are informed in part 
by observational data from high-income coun-
tries,12,13 where serious bacterial infections are 
less frequent, malaria is rare, and co-trimoxa-
zole is primarily used to prevent P. jirovecii pneu-
Table 2. Primary and Secondary Time-to-Event End Points.
End Point
Co-trimoxazole 
Prophylaxis 
Continued
(N = 376)
Co-trimoxazole 
Prophylaxis 
Stopped
(N = 382)
Hazard Ratio 
(95% CI)* P Value†
Primary efficacy end point: hospitalization 
or death — no. (%)
48 (13) 72 (19) 1.64 (1.14–2.37) 0.007
According to CD4 T-cell percentage at randomiza-
tion — no./total no. (%)
0.08
≥30% 23/237 (10) 46/238 (19) 2.15 (1.30–3.54)
15–29% 19/126 (15) 17/119 (14) 0.96 (0.50–1.85)
0–14% 6/13 (46) 9/25 (36) 0.81 (0.29–2.27)
According to ART monitoring strategy — no./ 
total no. (%)
0.69
CD4 T-cell monitoring 21/185 (11) 29/189 (15) 1.44 (0.82–2.52)
No CD4 T-cell monitoring 27/191 (14) 43/193 (22) 1.67 (1.03–2.71)
According to age at randomization — no./ 
total no. (%)
0.93
3–6 yr 24/176 (14) 33/158 (21) 1.69 (1.00–2.86)
7–12 yr 18/162 (11) 29/175 (17) 1.53 (0.85–2.75)
≥13 yr 6/38 (16) 10/49 (20) 1.38 (0.50–3.79)
According to country — no./total no. (%) 0.91
Uganda 40/283 (14) 60/286 (21) 1.59 (1.06–2.37)
Zimbabwe 8/93 (9) 12/96 (12) 1.51 (0.62–3.68)
Hospitalization or death due to malaria — no. (%)‡ 18 (5) 36 (9) 2.15 (1.22–3.78) 0.007
Hospitalization or death due to infection other than 
malaria — no. (%)‡
21 (6) 39 (10) 1.95 (1.15–3.32) 0.01
Malaria — no. (%) 39 (10) 77 (20) 2.21 (1.50–3.25) <0.001
Primary safety end point: grade 3 or 4 adverse event 
— no. (%)
55 (15) 64 (17) 1.20 (0.83–1.72) 0.33
Grade 4 adverse event — no. (%) 11 (3) 22 (6) 2.04 (0.99–4.22) 0.05
* Hazard ratios were stratified according to center, monitoring group, and treatment group (i.e., the randomization stratification factors; un-
stratified hazard ratios were similar), except for subgroup analyses in which numbers within individual subgroups were too small for further 
stratification.
† For subgroup analyses, the P values listed are for the test of heterogeneity. For other analyses, P values are for the log-rank test of stopping 
versus continuing prophylaxis.
‡ Post hoc analyses included the two main components of the composite end point (hospitalization or death due to malaria, and hospitaliza-
tion or death due to infection other than malaria). The numbers of participants do not add up to the total for the primary end point because 
a small number of participants were hospitalized for both malaria and infection other than malaria, and some were hospitalized only for a 
noninfectious disorder (Table S3 in the Supplementary Appendix).
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monia. Once children in those locations have 
good recovery of CD4 T cells during ART, the 
risk of opportunistic infections is low and cessa-
tion of co-trimoxazole appears to be safe. How-
ever, we found that co-trimoxazole continues to 
provide protection against bacterial infections 
and malaria in sub-Saharan Africa, despite good 
immune reconstitution during long-term ART.
The increase in hospitalizations among the 
participants who stopped receiving co-trimoxa-
zole was evident early and persisted throughout 
follow-up. It was observed in both a country 
where malaria is endemic (Uganda) and a coun-
try where malaria is not endemic (Zimbabwe). 
The risk of malaria requiring hospitalization, 
which was twice as high among participants 
who stopped receiving co-trimoxazole as it was 
among those who continued to receive co-trimox-
azole, was consistent with previous studies 
showing that co-trimoxazole prevents parasit-
emia4 and clinical malaria.1,21-23 A randomized 
trial24 involving ART-treated adults in Uganda 
similarly showed increased risks of malaria after 
co-trimoxazole was discontinued. Although the 
potential for increased antifolate resistance has 
raised concerns about more widespread use of 
co-trimoxazole,25 most studies have not shown 
an increase in resistance22,26-28; where high-level 
resistance has emerged, antifolates such as sul-
fadoxine and pyrimethamine still appear to be 
effective.21 Furthermore, guidelines now recom-
mend artemisinin-based first-line antimalarial 
treatment.29
In our study, participants who stopped receiv-
ing co-trimoxazole also had an increase in the 
number of hospitalizations for infection other 
than malaria, particularly pneumonia, septice-
mia, and meningitis — a finding that is consis-
tent with the major reductions in bacterial infec-
tions observed with co-trimoxazole in pre-ART 
trials involving children7,8 and adults.1,6 Co-tri-
moxazole provided protection against invasive 
bacterial infection even in a patient population 
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with a relatively high CD4 T-cell percentage (me-
dian, 33% in the ARROW trial vs. 11% in the 
Children with HIV Antibiotic Prophylaxis [CHAP] 
trial7). Our findings contrast with those of a 
previous observational U.S. study,13 which showed 
no increased risk of severe bacterial infection 
among ART-treated children who stopped receiv-
ing co-trimoxazole after good immune reconsti-
tution. However, studies involving adults in Af-
rica have shown that there is an ongoing risk of 
severe bacterial infection associated with rela-
tively high CD4 T-cell counts.30-33 Maintaining 
prophylaxis against a wide spectrum of gram-
positive and gram-negative organisms may there-
fore be important in sub-Saharan Africa, where 
rates of bacterial infection are high.
Like other studies,4,7,15,24 ours showed bene-
fits from co-trimoxazole prophylaxis in two 
countries with high rates of resistance to co-tri-
moxazole, for reasons that are unclear. Co-tri-
moxazole may retain sufficient antimicrobial 
activity to prevent severe bacterial disease, or its 
activity against other pathogens, including Myco-
bacterium tuberculosis34 and P. jirovecii, may have 
been underestimated. Since diagnostic capacity 
in the ARROW trial was limited, the diagnosis 
of most cases of severe bacterial pneumonia was 
presumptive; although an end-point review com-
mittee adjudicated all diagnoses, it is possible 
that some participants had tuberculosis, P. jirove-
cii pneumonia, or infection due to another or-
ganism, as previously reported.35 We observed 
fewer cases of tuberculosis among participants 
who stopped receiving co-trimoxazole than 
among those who continued to receive it (Table 
S2 in the Supplementary Appendix); however, 
most diagnoses of tuberculosis were presump-
tive, the numbers were small, and tuberculosis 
and bacterial coinfection is not unusual.35
One question is why the antibacterial activity 
of co-trimoxazole persists in children (those in 
our study had been receiving ART for 4 to 5 years 
by the date of trial closure) but wanes in adults.15 
Children generally have a higher risk of bacte-
rial infections than adults, and immune recon-
stitution is driven predominantly by repopula-
tion with naive CD4 T cells in children36 but 
not in adults; children may therefore still have 
poor pathogen-specific memory responses de-
spite long-term ART.
Stopping co-trimoxazole prophylaxis had no 
significant effect on growth in our study par-
ticipants, in contrast to the improved growth ob-
served among children who received co-trimoxa-
zole, as compared with those who received placebo, 
in the CHAP trial, which involved HIV-infected 
children who were not receiving ART.37 Children 
have rapid weight and height increases during 
ART,9 particularly during the first year38; any 
additional benefit of co-trimoxazole after 2 years 
of ART may be minimal.
In our study, children and adolescents who 
stopped receiving co-trimoxazole had higher rates 
of anemia, including potentially life-threatening 
(grade 4) events, than those who continued co-
trimoxazole. Although this may seem counterin-
tuitive, it is consistent with the results of the 
CHAP trial, in which children receiving co-tri-
moxazole who had not previously received ART 
had greater increases in the hemoglobin level 
than those receiving placebo.37 The high frequency 
of infection, particularly malaria, in children who 
stopped receiving co-trimoxazole could explain 
the rates of anemia in the ARROW trial. Alter-
natively, co-trimoxazole may reduce the immune 
activation that impairs erythropoiesis,39 either 
directly by means of immunomodulatory prop-
erties or indirectly by reducing the translocation 
of intestinal microbes.15 The greater increases in 
white-cell and neutrophil counts in participants 
who stopped receiving co-trimoxazole, as com-
pared with those who continued to receive it, are 
consistent with the potential myelosuppressive 
effects of co-trimoxazole.
The main limitation of our trial is the combi-
nation of the open-label design and the manage-
ment-based primary end point (hospitalization). 
However, the open-label design had the advan-
tage of reducing the pill burden in the prophy-
laxis-stopped group, thus allowing potential 
improvements in ART adherence to be evaluated. 
There was no cost to caregivers, so there was no 
bias from differences in the ability to pay for hos-
pital care between groups. We cannot rule out 
differences in preventive or health-seeking be-
havior among caregivers or differences among 
clinicians in the threshold for hospitalizing a 
patient. More participants in the prophylaxis-
stopped group might have been hospitalized 
owing to concerns about the cessation of co-tri-
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moxazole prophylaxis, although it is equally plau-
sible that more participants in the prophylaxis-
continued group were hospitalized owing to 
concerns about breakthrough infection during 
prophylaxis. The consistency across multiple (in-
cluding severe) end points and subgroups sug-
gests an underlying effect. Even if the real effect 
is smaller than observed, co-trimoxazole is inex-
pensive, costing only a few cents per day.
Our findings highlight the importance of co-
trimoxazole in treating HIV-infected children 
and adolescents in sub-Saharan Africa, even in 
the ART era. Current WHO recommendations11 
— that co-trimoxazole prophylaxis can be 
stopped in children older than 5 years of age 
who have adequate CD4 T-cell reconstitution 
(>350 CD4 T cells per cubic millimeter) after 
more than 6 months of ART — need to be re-
considered. Despite the inclusion of participants 
with more than 2 years of ART and high CD4 
T-cell counts (median count in participants >5 years 
of age, 720 per cubic millimeter), continued pro-
phylaxis with co-trimoxazole led to sustained 
reductions in hospitalization for a range of in-
fections, in areas where malaria is not endemic 
as well as in areas where it is endemic, with no 
evidence of variation across ages and with con-
sistent benefits with respect to secondary end 
points. Continued co-trimoxazole prophylaxis 
had an acceptable safety profile and was not as-
sociated with poor adherence to ART.
These findings argue strongly for long-term 
co-trimoxazole prophylaxis in conjunction with 
ART in children and adolescents in sub-Saharan 
Africa, until further evidence is available to guide 
decisions about cessation of prophylaxis. Wheth-
er the benefits of co-trimoxazole will wane over 
the long term is unknown, but given the persis-
tent risk we observed, co-trimoxazole will prob-
ably continue to provide a benefit after 2 years. 
Although an increase in the use of co-trimoxazole 
prophylaxis carries the risk of increased bacterial 
resistance in locations where co-trimoxazole is 
still used for first-line treatment, resistance rates 
are already high,1,4,7 and infections occurring in 
our study participants who had stopped receiving 
prophylaxis were often treated with broad-spec-
trum antibiotic agents, such as ceftriaxone. Long-
term operational research would usefully address 
both these issues. Achieving widespread benefits 
from co-trimoxazole for children in ART pro-
grams will require additional training of health 
workers and improved methods of drug-use fore-
casting and procurement of co-trimoxazole at 
health facilities to prevent depletion of stocks.40
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